F
FEMSelect
The developer the FDA cleared and CE Marked system for suturing ligaments of the pelvic floor as an approach to minimally-invasive Pelvic Organ Prolapse (POP) procedures
About FEMSelect
FemSelect is a medical technology company specializing in a minimally invasive, meshless system for treating uterine prolapse. The company's core product, EnPlace, anchors sutures to the pelvic floor ligaments without the use of transvaginal mesh, thereby eliminating mesh-related complications. FemSelect primarily serves women suffering from pelvic organ prolapse, a condition affecting 30-50% of women during their lifetime. The market for this solution is expanding rapidly due to the aging population. The business model involves selling the EnPlace system to healthcare providers and hospitals, generating revenue through product sales and potentially through licensing agreements. The company emphasizes quick patient recovery, with most patients resuming normal activities within 2-3 days and avoiding overnight hospital stays.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Tel Aviv-Yafo, Israel
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 69.5/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Women's Health, Non-Invasive medical devices and treatments, Femtech, Sustainable Development Goals, Tech for Patients, Biotech and Pharma
- Technology
- Deep Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2025 | — | — | RAD BioMed · Robin Hood Ventures · Nordwand Capital · TriVentures | ↗ |
| SERIES B✓Equity / VC | Oct 2022 | $9M | $36M | TriVentures · Keiretsu Forum · MEDA Angels · New Age Ventures | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for FEMSelect is 2.4K monthly website visits, down 20% over the last three months. FEMSelect's team declined 17.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Mid Atlantic Bio Angels
TriVentures
New Age Ventures
Keiretsu Forum- MAMEDA Angels
Keiretsu Capital- RVRobin Hood Ventures
- TPTransPacific Venture Partners
RAD BioMed
Nordwand Capital
Other known investors2 additional known investors
New York Angels
Teal Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about FEMSelect on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See FEMSelect’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.